Hematological Effects of 2',3'-Dideoxycytidine in Rabbits
Open Access
- 1 May 1992
- journal article
- research article
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 20 (3-1) , 367-375
- https://doi.org/10.1177/019262339202000307
Abstract
The antiviral nucleoside analogue 2',3'-dideoxycytidine (ddC) is a DNA chain terminator and/or inhibitor of human immunodeficiency virus (HIV) reverse transcriptase. We evaluated the effects of ddC in 36 New Zealand white rabbits. Three/sex were assigned to a control group and 5 treatment groups (10-250 mg/kg/ day) for 13 or 18 weeks. Blood samples were taken 1 week prior to treatment and weekly thereafter to termination with the exception of the 2 highest dose groups, where blood sample collection was terminated at week 13. Selected hematological analytes were measured weekly with the exception of prothrombin time (PT) and activated partial thromboplastin time (APTT). PT and APTT and selected biochemical analytes were measured prior to treatment, at 7 weeks, and after 13 weeks of treatment. All rabbits were necropsied. Giemsa and hematoxylin and eosin sections were prepared from methacrylate-embedded marrow. Hematological effects included decreases in red blood cell count, hemoglobin, hematocrit, and white blood cell count and increases in mean corpuscular volume and red cell distribution width. Platelets, platelet volume, PT, APTT, and mean corpuscular hemoglobin concentration values were variable or unchanged. Effects were dose-related, most were seen at 1 week, and they persisted to term. Bone marrow histopathologic changes included megalocytosis, erythroid hypoplasia, bizarre erythroid nuclear morphology, nuclear-cytoplasmic asynchrony, and increased mitotic figures. Lymphopenia caused by ddC plateaued at 2 weeks and persisted until termination. Heteropenia (neutropenia) was sporadic. Biochemical values for serum analytes were unchanged by treatment. The principal hematological effect of ddC upon the erythron was characterized as a nonregenerative macrocytic anemia with erythroid hypoplasia and megaloblastic erythropoiesis. We consider the anemia to be of bone marrow origin because of the morphologic changes observed here and produced by the effect of ddC on DNA synthesis in erythroid precursors and/or stromal cells.Keywords
This publication has 18 references indexed in Scilit:
- Alternating and intermittent regimens of zidovudine (3′-azido-3′-deoxythymidine) and dideoxycytidine (2′,3′-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complexThe American Journal of Medicine, 1990
- Pharmacokinetics of 2′,3′-Dideoxycytidine in Rats: Application to Interspecies Scale-upJournal of Pharmacy and Pharmacology, 1989
- Toxicity and efficacy of 2',3'-dideoxycytidine in clinical trials of pigtailed macaques infected with simian retrovirus type 2Antimicrobial Agents and Chemotherapy, 1989
- A comparison of three nucleoside analogs with anti-retroviral activity on immune and hematopoietic functions in mice: In vitro toxicity to precursor cells and microstromal environmentToxicology and Applied Pharmacology, 1989
- In vitro bone marrow toxicity of nucleoside analogs against human immunodeficiency virusAntimicrobial Agents and Chemotherapy, 1989
- Treatment of FeLV-induced immunodeficiency syndrome (FeLV-FAIDS) with controlled release capsular implantation of 2′,3′-dideoxycytidineAntiviral Research, 1989
- Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides.The Journal of Experimental Medicine, 1988
- The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell speciesBiochemical Pharmacology, 1988
- Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogsJournal of Medicinal Chemistry, 1987
- Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivityBiochemical Pharmacology, 1986